009420.KS
Hanall Biopharma Co.,Ltd
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 53,900.00
−2.00%Margins
Gross margin
52.1%
EBITDA margin
-8.3%
EBIT margin
2.4%
Net margin
-15.3%
FCF margin
-3.3%
-15.4%
Return on equity
-10.4%
Return on assets
1.9%
Return on invested capital
0.67x
Asset turnover
-KRW 1.2B
Cash from operations
KRW 578
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026